ReviewMediators of inflammation2013
Biological treatments: new weapons in the management of monogenic autoinflammatory disorders.
Review in Mediators of inflammation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 73 citations in OpenAlex.
- Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome.Annals of the rheumatic diseases · 2017Trial
- Idiopathic Raynaud's Phenomenon and Vitamin D Deficiency in Children and Adolescents: An Exploratory Single-Center Retrospective Observational Study Throughout the Period 2010-2025.Journal of clinical medicine · 2026Article
- Sleep and Cytokines: A Bidirectional Dialogue Involving Rest and Immunity.Children (Basel, Switzerland) · 2026Review
- NLRP12 as a Regulator of Inflammation: Insights into the Correlation with Autoinflammatory Disorders.Genes · 2026Review
- Investigating Properties of Palmitoylethanolamide in Physiology and Disease: Far Beyond an Anti-Inflammatory Shield.Diseases (Basel, Switzerland) · 2026Review
- Gut microbiota alliance to shape sceneries of familial Mediterranean fever: a scoping review detailing difference between children and adults.Frontiers in immunology · 2026Article
- Article
- Overview of the rarest causes of fever in newborns: handy hints for the neonatologist.Journal of perinatology : official journal of the California Perinatal Association · 2021Review
- Article
- Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide.Frontiers in immunology · 2020Review
- Treating TNF Receptor Associated Periodic Fever Syndrome in End-Stage Renal Failure.Case reports in nephrology · 2019Article
- In silico validation of the Autoinflammatory Disease Damage Index.Annals of the rheumatic diseases · 2018Article
- From autoinflammation to autoimmunity: old and recent findings.Clinical rheumatology · 2018Review
- A Comprehensive Overview of the Hereditary Periodic Fever Syndromes.Clinical reviews in allergy & immunology · 2018Review
- Tumor necrosis factor-associated periodic syndrome in adults.Rheumatology international · 2018Review
- Monogenic Periodic Fever Syndromes: Treatment Options for the Pediatric Patient.Paediatric drugs · 2017Review
- HumanThe Journal of experimental medicine · 2017Article
- Pyoderma gangrenosum-a novel approach?Wiener medizinische Wochenschrift (1946) · 2017Review
- Lung Involvement in Children with Hereditary Autoinflammatory Disorders.International journal of molecular sciences · 2016Review
- Systemic and organ involvement in monogenic autoinflammatory disorders: a global review filtered through internists' lens.Internal and emergency medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of monogenic autoinflammatory disorders, an expanding group of hereditary diseases characterized by apparently unprovoked recurrent episodes of inflammation, without high-titre autoantibodies or antigen-specific T cells, has been revolutionized by the discovery that several of these conditions are caused by mutations in proteins involved in the mechanisms of innate immune response, including components of the inflammasome, cytokine receptors, receptor antagonists, and oversecretion of a network of proinflammatory molecules. Aim of this review is to synthesize the current experience and the most recent evidences about the therapeutic approach with biologic drugs in pediatric and adult patients with monogenic autoinflammatory disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.